Botulinum Toxin Type A (ENT)
Brand names: Botox, Dysport, Xeomin
Botulinum toxin type A is given by targeted local injection for several ENT indications, including spasmodic (laryngeal) dysphonia, troublesome sialorrhoea and certain cricopharyngeal and salivary-gland disorders.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It blocks presynaptic release of acetylcholine at the neuromuscular junction and cholinergic autonomic terminals, producing temporary, dose-dependent weakening of injected muscle or reduction of glandular secretion.
Prescribing in practice
- Different botulinum toxin products are not interchangeable in units and dosing errors can cause toxin spread with serious effects such as dysphagia, aspiration or breathing difficulty, so the specific product and indication must be confirmed and injection performed by appropriately trained clinicians.
- Effects are temporary, developing over days and lasting some months, so repeat treatment is generally needed.
- Use cautiously in patients with neuromuscular disorders (such as myasthenia gravis) or pre-existing swallowing problems, who are more prone to adverse effects.
Monitoring
Assess the targeted clinical effect and watch for local spread effects such as new or worsening swallowing or voice difficulty after each treatment.
Counselling the patient
- The effect is temporary and usually needs repeating after a few months.
- Seek urgent help for difficulty swallowing, breathing or speaking after injection.
- Voice or swallowing may change for a short period after laryngeal injection.
Evidence & guidelines
Local botulinum toxin injection is the established treatment for adductor spasmodic dysphonia and an option for refractory sialorrhoea.
Reference: MHRA Botulinum Toxin Guidance 2012; NICE TA107 (chronic sialorrhoea); Borodic et al. Laryngoscope 1992 (spasmodic dysphonia); BAO-HNS Frey's Syndrome Guideline; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Train-of-Four (TOF) Neuromuscular Monitoring · Neuromuscular Blockade
- SCORE2-Diabetes 10-Year CVD Risk in Type 2 Diabetes · Cardiovascular Risk
- Insulin TDD Estimator · Diabetes
- AUSDRISK — Australian Type 2 Diabetes Risk Tool · Diabetes Risk
- CANRISK — Canadian Diabetes Risk Questionnaire · Diabetes Risk
- Insulin Correction Factor (ICF/ISF) · Insulin Management
- Adult Upper Airway Obstruction (Stridor) · DAS 2015 unanticipated difficult airway; RCEM
- Epistaxis Management · ENT-UK / NICE
- Acute Otitis Media · NICE NG91 2018
- Tonsillitis and Sore Throat · NICE NG84 2018
- Benign Paroxysmal Positional Vertigo · NICE CG124 / AAO-HNS Guidelines
- Acute Rhinosinusitis · NICE NG79 2017 / EPOS 2020